SCYX Description — SCYNEXIS, Inc.

SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and Co. has commenced the commercialization of BREXAFEMME in the U.S. Co. also is continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of invasive fungal infections caused by Candida spp. (including C. auris) and Aspergillus spp. in hospitalized patients.

Company Name: 
Number of ETFs Holding SCYX: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   SCYX Weight   SCYX Amount 
 VTI   0.00%   $2,784,574         
 VXF   0.00%   $843,449         
 IWC   0.02%   $198,111         
 ITOT   0.00%   $$,127         
Quotes delayed 20 minutes

Email EnvelopeFree SCYX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding SCYX | SCYNEXIS, Inc. | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.